Abstract
The treatment landscape for patients with established or at high risk for cardiovascular disease and type 2 diabetes mellitus has entirely changed over the past decade, with the introduction of several anti-hyperglycemic agents. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists are two anti-hyperglycemic classes which have been of special interest after multiple large cardiovascular disease (CVD) outcomes studies have demonstrated superiority of these agents compared to placebo for major adverse CVD events and in some cases, hospitalization for heart failure. Despite the dramatic results of these trials, only recently have we began to understand the mechanisms underlying these CVD benefits. Here we review the underlying mechanisms which have the greatest plausibility for both of these agents including the impact of ventricular loading conditions, direct effects on cardiac structure and function, myocardial energetics and sodium/hydrogen exchange for SGLT2 inhibitors, and the anti-atherosclerotic, anti-inflammatory, and modulation of endothelial function for GLP-1 agonists.
Citations
Feb 27, 2020·Hospital Practice·Eiji KutohRumi Kurihara
Apr 25, 2020·Journal of the American Heart Association·Ignatios IkonomidisVaia Lambadiari
May 22, 2020·Circulation Research·Marie-Eve PichéJean-Pierre Després
Jun 23, 2020·Obesity·Salvatore CarboneCarl J Lavie
Mar 10, 2020·Canadian Journal of Physiology and Pharmacology·Chris R TriggleMorley D Hollenberg
Jun 18, 2020·Expert Review of Cardiovascular Therapy·Sara SotirakosRichard Armstrong
Jul 12, 2020·Journal of Cellular and Molecular Medicine·Yusuf OlgarBelma Turan
Jul 23, 2020·Current Opinion in Cardiology·Subodh VermaMikhail N Kosiborod
Jul 1, 2020·Journal of Cardiopulmonary Rehabilitation and Prevention·Barry A FranklinLeonard A Kaminsky
Mar 29, 2020·JAMA : the Journal of the American Medical Association·Mark C PetrieJohn J V McMurray
Oct 2, 2020·Cardiovascular Diabetology·Martin H SørensenPeter Gæde
Jun 26, 2020·JAMA Cardiology·Michael C HonigbergMuthiah Vaduganathan
Oct 6, 2020·Future Cardiology·Sara Sotirakos
Jan 27, 2021·Cardiovascular Diabetology·Yi-Wen YuJian Zhang
Jan 29, 2021·International Journal of Molecular Sciences·Nguyen Ngoc TrangYi-Jen Chen
Dec 29, 2020·Post Reproductive Health·Satish Jankie, Lexley Maureen Pinto Pereira
Jan 18, 2021·JACC. Cardiovascular Imaging·Tamique MasonKim A Connelly
Nov 6, 2020·Heart Failure Reviews·Mieczysław DutkaMichał Ćwiertnia
Mar 15, 2021·Progress in Cardiovascular Diseases·Carl J Lavie
Apr 7, 2021·British Journal of Pharmacology·Neil TandayNigel Irwin
Jun 4, 2021·Current Problems in Cardiology·Gauravpal S GillVenkata M Alla
Aug 21, 2021·Progress in Cardiovascular Diseases·Carl J Lavie
Oct 1, 2021·Diabetes Research and Clinical Practice·Eric Ho Man TangBernard Man Yung Cheung
Oct 27, 2020·Journal of the American Association of Nurse Practitioners·Dawn M Battise, Jacqueline L Olin